Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to investigate the efficacy, safety and tolerability of
linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM
patients on empagliflozin 10 mg or 25 mg and maximum tolerated dose of metformin. The primary
objective of efficacy evaluation is planned after 24 weeks of treatment. The study is
designed to show superiority of the combination of empagliflozin and linagliptin over
empagliflozin alone.